Paucimannosylation Is a Prognostic Marker in High-grade Serous Ovarian Cancer
Paucimannosylation, indicated by the presence of PMEs, is present in both tumor and immune cells in high-grade serous ovarian cancer. The prognostic implication of PMEs seems to be cell type-dependent. While immune cell paucimannosylation was associated with improved survival, tumor cell paucimannosylation was associated with reduced survival.
Authors
- Dominique Könsgen
- Lucia Otten
- Carolin Schröder (ORCID: https://orcid.org/0000-0001-5045-9643)
- Eva Maria Egger
- Thore Thiesler (ORCID: https://orcid.org/0000-0002-6796-7772)
- Michael H. Muders (ORCID: https://orcid.org/0000-0003-3020-9692)
- Sarah Förster (ORCID: https://orcid.org/0000-0002-3361-6085)
- ALEXANDER MUSTEA
- LINA ADLOFF
- MILKA MARINOVA
Institutions
- University Hospital Bonn (DE)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-12-30
- DOI
- https://doi.org/10.21873/anticanres.17925
- Primary Topic
- Proteoglycans and glycosaminoglycans research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Rheinische Friedrich-Wilhelms-Universität Bonn